Invasive pneumococcal disease in Latin America: serotype distribution and vaccine coverage among adults in Mexico, Brazil, and Argentina.

Amanda Martino¹, Juan Urrego-Reyes², Jan Cervenka³, Mohan Kumar Paluru⁴, Nicole Cossrow⁵

¹Merck & Co., Inc., Rahway, NJ, USA. Electronic address: amanda.donohue@merck.com.

²MSD Colombia, Bogotá D.C, Colombia.

³MSD Czech Republic, Prague, Czech Republic.

⁴Inovalon India Pvt Ltd, Hyderabad, India.

⁵Merck & Co., Inc., Rahway, NJ, USA.

PubMed DOI

Abstract

BACKGROUND: Invasive pneumococcal disease (IPD) causes substantial morbidity and mortality among adults in Latin America. Despite high pediatric pneumococcal conjugate vaccine (PCV), uptake, adult coverage remains low, and residual IPD burden persists. Among currently available PCVs, PCV21 and PCV20 are the newest higher-valency formulations. PCV21 includes eight unique serotypes to address residu…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.